A comprehensive view of Horizon Therapeutics Plc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
Horizon Therapeutics reports Phase 3 trial shows Uplizna inebilizumab-cdon injectable effective for patients with neuromyelitis optica spectrum disorder after one attack; NMOSD most common in women, people of African, Asian descent
Published:
April 06, 2022
by Horizon Therapeutics Plc.
|
Horizon Therapeutics announces FDA has granted priority review of license application for Krystexxa pegloticase injection plus methotrexate to treat uncontrolled gout; Krystexxa is only approved biologic treatment for gout
Published:
March 16, 2022
by Horizon Therapeutics Plc.
|
Ireland's Horizon Therapeutics submits supplemental biologics license application to US FDA for KRYSTEXXA, or pegloticase injection, with methotrexate for adults with uncontrolled gout; submission based on randomized trial data showing 71% response rate
Published:
January 13, 2022
by Horizon Therapeutics Plc.
|
Ask us about our Health Care Sector market view
Trending Chart
Interactive chart with headline count